1911

Establishment of the Company by Ioannis Lavidas

1914

Launch of Digitaline, a cardiovascular pharmaceutical product which opened a new era in modern therapeutics in Greece

1958

Launch of Nitroglycerin Controlled Release, opening a new chapter in the history of Cardiology

1976

Dr. Athanase Lavidas takes helm with new management team

1977

Collaboration with L’Oréal - first to sell cosmetics through pharmacies in Greece

1979

Completion of production unit for the manufacturing of pharmaceutical and cosmetic products

Launch of the antilice Ivaliten a blockbuster at the time

1985

Establishment of R&D department focused on drug delivery technologies

1988

Launch of Avon Cosmetics in Greece. Lavipharm creates a new distribution channel in the Greek market by introducing door-to-door sales

1989

Establishment of Laboratoires Lavipharm in Paris

1992

Joint Ventures with Synthélabo-France (Synthélabo -Lavipharm) and L’Oreal Cosmetique Active (Lavicosmetica)

Launch of the dermocosmetic brand Castalia, developed by Lavipharm

1993

Completion of an integrated production unit for transdermals which remains until today one of the few in Europe

1994

Establishment of the wholesaling and distribution center (LAS)

1995

Listing of Lavipharm S.A. on the Athens Stock Exchange

Launch of nitroglycerin transdermal patch in Italy and France

1996

Acquisition of a U.S. based R&D unit specialised in TDDSs (now Lavipharm Laboratories Inc)

1997

Launch of patented acne epidermal patch developed in-house in 40 countries by L’Oreal

1999

Lavipharm was included in Europe’s 500 fastest growing companies

2000

Acquisition of Hitex (France) and 30% of Phasex (U.S.) entering the Super Critical Fluid Technologies (SCF) area

2002

Re-launch of the traditional Greek analgesic Algon®

2003

Nomination of a Business Award for Innovation

2004

Launch of Castalia’s products in the Chinese market

2006

FDA approval of Lavipharm's fentanyl transdermal system in the USA

Lavipharm is listed as one of 1000 top companies that invest in the R&D Sector according to the European Innovation Scoreboard (EIS)

2007

Fentanyl transdermal system’s launch in Greece

2008

Fentanyl transdermal system’s launch in Germany

Co-marketing with Pfizer Hellas for Lavipharm’s Trinipatch™ Transdermal System in the Greek market

2009

Regulatory approval of fentanyl transdermal system in Austria, Belgium, Ireland, Italy, Norway, Portugal, Spain, Sweden and France

2010

DCP Regulatory approval for Lavipharm’s fentanyl transdermal system in 20 more countries

Pfizer Hellas markets Lavipharm’s Dolfen™ in Greece